Hutchison China Meditech Limited Initiates Phase I of Novel FGFR Inhibitor HMPL-453 (8060W)
14 February 2017 - 6:07PM
UK Regulatory
TIDMHCM
RNS Number : 8060W
Hutchison China Meditech Limited
14 February 2017
Chi-Med Initiates First-In-Human Clinical Trial of Novel FGFR
Inhibitor HMPL-453 in Australia
London: Tuesday, February 14, 2017: Hutchison China MediTech
Limited ("Chi-Med") (AIM/Nasdaq: HCM) today announces that it has
initiated the first-in-human ("FIH") Phase I clinical trial of
HMPL-453 in Australia. HMPL-453 is a novel, highly selective and
potent small molecule inhibitor targeting fibroblast growth factor
receptor ("FGFR"). The first drug dose was administered on February
14, 2017.
FGFRs are a sub-family of receptor tyrosine kinases. Activation
of FGFR signaling pathways is central to several biological
processes, including angiogenesis, tissue growth and repair. Given
its complexity and critical role in a number of important
physiological processes, aberrant FGFR signaling has been found to
be a driving force in tumor growth, promotion of angiogenesis, as
well as, conferring resistance to anti-tumor therapies. To date,
there are no approved therapies specifically targeting the FGFR
signaling pathway.
The FIH dose-escalation trial aims to evaluate the safety,
tolerability, pharmacokinetics and preliminary anti-tumor activity
of HMPL-453 in patients with advanced or metastatic solid
malignancies, who have failed or are unable to tolerate standard
therapies or for whom no standard therapies exist. This open-label
study consists of two preliminary phases, a dose-escalation (stage
1) and a dose-expansion stage (stage 2).
In pre-clinical studies, HMPL-453 demonstrated superior potency
and better kinase selectivity as compared to other drugs in the
same class, as well as a favorable safety profile. Additional
details about this study may be found at clinicaltrials.gov, using
identifier NCT02966171.
About Chi-Med
Chi-Med is an innovative biopharmaceutical company which
researches, develops, manufactures and sells pharmaceuticals and
healthcare products. Its Innovation Platform, Hutchison MediPharma
Limited, focuses on discovering and developing innovative
therapeutics in oncology and autoimmune diseases for the global
market. Its Commercial Platform manufactures, markets, and
distributes prescription drugs and consumer health products in
China.
Chi-Med is majority owned by the multinational conglomerate CK
Hutchison Holdings Limited (SEHK: 0001). For more information,
please visit: www.chi-med.com.
Forward-Looking Statements
This announcement contains forward-looking statements within the
meaning of the "safe harbor" provisions of the U.S. Private
Securities Litigation Reform Act of 1995. These forward-looking
statements reflect Chi-Med's current expectations regarding future
events, including its expectations for the clinical development of
HMPL-453, plans to initiate clinical studies for HMPL-453, its
expectations as to whether such studies would meet their primary or
secondary endpoints, and its expectations as to the timing of the
completion and the release of results from such studies.
Forward-looking statements involve risks and uncertainties. Such
risks and uncertainties include, among other things, assumptions
regarding enrollment rates, timing and availability of subjects
meeting a study's inclusion and exclusion criteria, changes to
clinical protocols or regulatory requirements, unexpected adverse
events or safety issues, the ability of drug candidate HMPL-453 to
meet the primary or secondary endpoint of a study, to obtain
regulatory approval in different jurisdictions, to gain commercial
acceptance after obtaining regulatory approval, the potential
market of HMPL-453 for a targeted indication and the sufficiency of
funding. Existing and prospective investors are cautioned not to
place undue reliance on these forward-looking statements, which
speak only as of the date hereof. For further discussion of these
and other risks, see Chi-Med's filings with the U.S. Securities and
Exchange Commission and on AIM. Chi-Med undertakes no obligation to
update or revise the information contained in this announcement,
whether as a result of new information, future events or
circumstances or otherwise.
Inside Information
This announcement contains inside information for the purposes
of Article 7 of Regulation (EU) No 596/2014.
Contacts
Investor Enquiries
Christian Hogg, CEO +852 2121 8200
International Media Enquiries
Anthony Carlisle, +44 7973 611 888 (Mobile) anthony.carlisle@cdrconsultancy.co.uk
Citigate Dewe Rogerson
U.S. Based Media Enquiries
Brad Miles, BMC Communications +1 (917) 570 7340 (Mobile) bmiles@bmccommunications.com
Susan Duffy, BMC Communications +1 (917) 499 8887 (Mobile) sduffy@bmccommunications.com
Investor Relations
Matt Beck, The Trout Group +1 (917) 415 1750 (Mobile) mbeck@troutgroup.com
David Dible, +44 7967 566 919 (Mobile) david.dible@citigatedr.co.uk
Citigate Dewe Rogerson
Panmure Gordon (UK) Limited
Richard Gray / Andrew Potts +44 (20) 7886 2500
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCTIMRTMBMBMIR
(END) Dow Jones Newswires
February 14, 2017 02:07 ET (07:07 GMT)
Hutchmed (china) (LSE:HCM)
Historical Stock Chart
From Apr 2024 to May 2024
Hutchmed (china) (LSE:HCM)
Historical Stock Chart
From May 2023 to May 2024